Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Rhea-AI Summary

Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY), a clinical stage company focused on developing small molecule medicines for inflammatory and fibrotic disorders, particularly kidney diseases, has announced its upcoming participation in two virtual investor conferences.

Management will present at the mwb online Health Care Conference on July 1, 2025, at 12:00 pm CEST, and the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 pm CEST / 9:00 am EDT. CEO Frank Weber and COO Julia Neugebauer will represent the company at both events.

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences

Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences:

mwb online Health Care Conference
Date: July 1, 2025
Presentation Time: 12:00 pm CEST
Attendees: Frank Weber, CEO; Julia Neugebauer, COO
Virtual conference
Link to conference https://research-hub.de/events/registration/2025-07-01-12-00/VVY-NA

H.C. Wainwright 4^th Annual Kidney Virtual Conference
Date: July 14, 2025
Presentation Time: 3:00 pm CEST / 9:00 am EDT
Attendees: Frank Weber, CEO; Julia Neugebauer, COO
Virtual conference
Link to conference https://hcwevents.com/kidneyconference/

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu

Attachment

• 20250627_conf July 2025_v_F

FAQ

When is Vivoryon Therapeutics (VVY) presenting at the mwb online Health Care Conference?

Vivoryon will present at the mwb online Health Care Conference on July 1, 2025 at 12:00 pm CEST.

When is Vivoryon's presentation at the H.C. Wainwright Kidney Conference 2025?

Vivoryon will present at the H.C. Wainwright Kidney Conference on July 14, 2025 at 3:00 pm CEST / 9:00 am EDT.

Who will represent Vivoryon Therapeutics at the upcoming investor conferences?

CEO Frank Weber and COO Julia Neugebauer will represent Vivoryon at both conferences.

How can investors access Vivoryon's conference presentations?

Investors can access the presentations through virtual conference links at research-hub.de for the mwb conference and hcwevents.com/kidneyconference for the H.C. Wainwright conference.

What is Vivoryon Therapeutics' main business focus?

Vivoryon is a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases.